Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Understanding a focused medical device company's financial health requires navigating regulatory filings that detail product revenue, manufacturing costs, and market dynamics. Embecta Corp's SEC documents reveal how the diabetes care business performs across geographic regions and distribution channels.
The company's 10-K annual reports break down revenue by product category and geography, showing how pen needle and syringe sales contribute to overall performance. These filings also detail manufacturing operations, supplier relationships, and the regulatory landscape affecting medical device companies. Our AI summaries extract these insights without requiring you to parse hundreds of pages of financial statements.
Quarterly 10-Q filings track seasonal patterns in diabetes care product demand and provide updates on gross margins, operating expenses, and cash flow. For a single-segment company like Embecta, these reports offer a clear view of business trajectory without the complexity of multi-division conglomerates.
Form 4 insider transactions show when executives and directors buy or sell EMBC shares. Monitoring these filings can reveal management confidence levels, particularly around earnings releases or strategic announcements.
The company's DEF 14A proxy statements detail executive compensation structures, board composition, and governance practices. These documents explain how leadership incentives align with shareholder interests in the diabetes care market.
8-K filings announce material events including earnings releases, dividend declarations, and corporate governance changes. Our platform delivers these updates with AI-generated explanations that clarify what each filing means for investors following the diabetes care sector.
Embecta Corp. is calling a virtual 2026 Annual Meeting on February 11, 2026, for stockholders of record as of December 15, 2025. Stockholders are being asked to elect seven directors for one-year terms, ratify Ernst & Young LLP as independent auditors for fiscal 2026, approve an advisory “say-on-pay” vote on named executive officer compensation, and approve an amendment to the 2022 Employee and Director Equity-Based Compensation Plan that would add 2,430,000 shares of common stock for future equity awards.
The Board highlights that 6 of 7 director nominees are independent and 71% are ethnically and/or gender diverse, and it uses majority voting, annual elections, proxy access and share ownership guidelines. Embecta emphasizes a pay-for-performance compensation philosophy, with a significant portion of executive and director pay delivered in equity. Audit fees paid to Ernst & Young LLP were $6,335,000 in fiscal 2025, and the Board unanimously recommends voting FOR all four proposals.
Embecta Corp. (EMBC)
Pen needles are its key product, generating about $784 million, or 73%, of net revenues for the year ended September 30, 2025. As of that date, Embecta held about 655 patents and 455 trademark registrations worldwide, and had roughly 1,850 employees, including about 700 in the U.S. The company reports a non‑affiliate equity market value of approximately $732 million as of March 31, 2025 and 58,512,841 common shares outstanding as of November 18, 2025.
Major risks include intense competition and rapid technological change in diabetes treatment, heavy dependence on a few products and large distributors, reliance on Becton, Dickinson and Company for cannula supply and certain services, reimbursement and pricing pressure from payers worldwide, compliance with complex global regulatory regimes, significant international and geopolitical exposure, trade and tariff uncertainty, and obligations and limitations arising from its 2022 separation from BD and related debt and tax agreements.
Embecta Corp. (EMBC) announced that it has released its financial results for the quarter and fiscal year ended September 30, 2025. The company reported these results in a press release dated November 25, 2025, which is included as an exhibit to the current report. This filing mainly serves to formally notify investors that the earnings information is available and to make the related press release part of the company’s public disclosures.
Embecta Corp. reported board leadership changes and one immediate director resignation. On November 17, 2025, director David A. Albritton resigned from the board and its Corporate Governance and Nominating Committee and Technology, Quality and Regulatory Committee for personal reasons, effective immediately, and the board size was reduced from nine to eight members. The company stated his resignation was not due to any disagreement with its operations, policies or practices. Also on November 17, 2025, Non-Executive Chairman LTG (Ret.) David F. Melcher informed Embecta he will not stand for re-election at the 2026 annual meeting, also not due to any disagreement. The independent directors expect to appoint CEO Devdatt (Dev) Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective upon Melcher’s departure.
Embecta Corp. Schedule 13G disclosure shows passive beneficial ownership positions by American Century entities and Stowers Institute in Embecta common stock. American Century Investment Management, American Century Companies and Stowers Institute report aggregate beneficial ownership of 5,195,948 shares (8.9% of the class), while American Century Capital Portfolios reports 3,460,379 shares (5.9% of the class). The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also notes that ACIM acts as investment adviser to accounts holding these securities and that no single ACIM client owns more than 5% of the class.
Jean Casner, Chief Human Resources Officer of Embecta Corp. (EMBC), reported a transaction on 08/09/2025 affecting her direct holdings of the issuer's common stock. The filing shows 916 shares were withheld in connection with the vesting of restricted stock units, with a reported price of $12.28 per share. After the transaction the reporting person held 48,798.926 shares beneficially in a direct ownership form. The filing includes an explanation that the withheld shares satisfied withholding tax obligations and that the reported share total includes stock dividends.
The form is signed by a power of attorney on behalf of the reporting person and incorporates a referenced power of attorney dated July 19, 2023.
Embecta Corp. (EMBC) Q3 FY2025 highlights: For the three months ended June 30, 2025 revenues were $295.5 million versus $272.5 million a year earlier and net income was $45.5 million versus $14.7 million. Diluted EPS was $0.78 versus $0.25. For the nine months ended June 30, 2025 revenues were $816.4 million versus $837.0 million and net income was $69.0 million versus $63.7 million.
Key operating and balance sheet items: Gross profit for the quarter was $197.1 million; operating income was $94.0 million. Cash and equivalents were $230.6 million at June 30, 2025. Long-term debt (net of discounts and issuance costs) was $1,458.8 million and total principal outstanding was $1,489.1 million. Total assets were $1,157.3 million and total equity was negative $669.6 million.
- Restructuring: Patch Pump charges totaled $34.3 million and a 2025 restructuring plan added $3.5 million during the nine months.
- Cash flow: Net cash provided by operating activities was $107.7 million for the nine months.
- Receivables: $26.2 million of receivables were sold during the period.
Embecta Corp. furnished a press release announcing results for the quarter ended June 30, 2025. The company submitted an 8-K to share this update and included the full press release as Exhibit 99.1. The filing notes the update relates to results of operations and financial condition. Shares trade on Nasdaq under EMBC.
FAQ
What is the current stock price of Embecta (EMBC)?
What is the market cap of Embecta (EMBC)?
